Kyntra Bio, Inc. (KYNB)
| Market Cap | 32.51M -30.1% |
| Revenue (ttm) | 4.62M -37.2% |
| Net Income | 183.19M |
| EPS | 45.27 |
| Shares Out | 4.05M |
| PE Ratio | 0.18 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,776 |
| Open | 7.85 |
| Previous Close | 7.97 |
| Day's Range | 7.79 - 8.06 |
| 52-Week Range | 6.32 - 12.58 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 39.00 (+385.68%) |
| Earnings Date | Nov 9, 2026 |
About KYNB
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for KYNB stock is "Buy." The 12-month stock price target is $39.0, which is an increase of 385.68% from the latest price.
News
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Inv...
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
Kyntra Bio (KYNB) announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, materially reducing its payment obligations under the agree...
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoeb...
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
“We continue to make progress across our oncology and rare disease portfolio and remain laser-focused on advancing toward our goal of initiating a pivotal Phase 3 trial of roxadustat in…
Kyntra Bio Earnings Call Transcript: Q2 2026
Clinical programs for FG-3246 in mCRPC and roxadustat in lower risk MDS advanced, with key trials on track and strong cash reserves supporting operations into 2028. Q2 2026 saw a return to net income and increased R&D investment.
Kyntra Bio Earnings release: Q2 2026
Kyntra Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kyntra Bio Quarterly report: Q2 2026
Kyntra Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kyntra Bio Slides: Q2 2026
Kyntra Bio has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the second quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Kyntra Bio (KYNB) with an Outperform rating and $35 price target citing “optimism” about lead programs FG-3246 and FG-3180 to address the persistent unmet need among…
Kyntra Bio Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification. All proposals passed with strong support, and final voting results will be filed with the SEC.
Kyntra Bio to present additional MATTERHORN trial data at EHA
Kyntra Bio (KYNB) announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndro...
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patient...
Kyntra Bio initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $30 price target The company has a first-in-class CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration...
Kyntra Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue growth and reduced expenses, with key clinical programs advancing as planned. FG-3246/FG-3180 phase II trial is on track for interim analysis in Q4 2026, and roxadustat is set for phase III initiation in H2 2026. Cash runway extends into 2028.
Kyntra Bio Earnings release: Q1 2026
Kyntra Bio released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Kyntra Bio Slides: Q1 2026
Kyntra Bio has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 11, 2026.
Kyntra Bio Quarterly report: Q1 2026
Kyntra Bio has published its Q1 2026 quarterly earnings report on May 11, 2026.
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
Kyntra Bio to Report First Quarter 2026 Financial Results
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a ...
Kyntra Bio Proxy statement: Proxy filing
Kyntra Bio filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Kyntra Bio Proxy statement: Proxy filing
Kyntra Bio filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Kyntra Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its business, repaid debt, and now focuses on advancing its ADC FG-3246 and PET imaging agent FG-3180 in mCRPC, with interim Phase II data expected in H2 2024. Roxadustat is being prepared for a Phase III trial in lower-risk MDS, with funding or partnership options under evaluation.
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-1...
Kyntra Bio Earnings Call Transcript: Q4 2025
2025 marked a transformational year with the sale of FibroGen China, debt repayment, and rebranding, extending cash runway into 2028. FG-3246 and FG-3180 advanced in mCRPC with promising early data, while roxadustat progressed in MDS with orphan drug status and a phase III trial planned for late 2026.